APLS vs AZN

APLS exhibits weak financial health per the Piotroski F-Score of 4/9, indicating a fragile foundation despite some positive gross margins and cash reserves. The company is unprofitable with negative operating margins and declining revenue, while insider selling activity and a bearish technical trend signal pessimism. Although the Graham Number ($3.44) and intrinsic value ($1.26) suggest deep undervaluation, the current price of $18.94 reflects high growth expectations that are not supported by fundamentals. The absence of an Altman Z-Score raises concern about default risk, especially given a debt/equity ratio of 1.28 and negative earnings. Analysts recommend 'buy' with a target of $33.60, but this optimism appears disconnected from deteriorating operational and financial trends.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.